Cargando…

Neuroinflammation After COVID-19 With Persistent Depressive and Cognitive Symptoms

IMPORTANCE: Persistent depressive symptoms, often accompanied by cognitive symptoms, commonly occur after COVID-19 illness (hereinafter termed COVID-DC, DC for depressive and/or cognitive symptoms). In patients with COVID-DC, gliosis, an inflammatory change, was suspected, but measurements of gliosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Braga, Joeffre, Lepra, Mariel, Kish, Stephen J., Rusjan, Pablo. M., Nasser, Zahra, Verhoeff, Natasha, Vasdev, Neil, Bagby, Michael, Boileau, Isabelle, Husain, M. Ishrat, Kolla, Nathan, Garcia, Armando, Chao, Thomas, Mizrahi, Romina, Faiz, Khunsa, Vieira, Erica L., Meyer, Jeffrey H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233457/
https://www.ncbi.nlm.nih.gov/pubmed/37256580
http://dx.doi.org/10.1001/jamapsychiatry.2023.1321
Descripción
Sumario:IMPORTANCE: Persistent depressive symptoms, often accompanied by cognitive symptoms, commonly occur after COVID-19 illness (hereinafter termed COVID-DC, DC for depressive and/or cognitive symptoms). In patients with COVID-DC, gliosis, an inflammatory change, was suspected, but measurements of gliosis had not been studied in the brain for this condition. OBJECTIVE: To determine whether translocator protein total distribution volume (TSPO V(T)), a marker of gliosis that is quantifiable with positron emission tomography (PET), is elevated in the dorsal putamen, ventral striatum, prefrontal cortex, anterior cingulate cortex, and hippocampus of persons with COVID-DC. DESIGN, SETTING, AND PARTICIPANTS: This case-control study conducted at a tertiary care psychiatric hospital in Canada from April 1, 2021, to June 30, 2022, compared TSPO V(T) of specific brain regions in 20 participants with COVID-DC with that in 20 healthy controls. The TSPO V(T) was measured with fluorine F 18–labeled N-(2-(2-fluoroethoxy)benzyl)-N-(4-phenoxypyridin-3-yl)acetamide ([(18)F]FEPPA) PET. MAIN OUTCOMES AND MEASURES: The TSPO V(T) was measured in the dorsal putamen, ventral striatum, prefrontal cortex, anterior cingulate cortex, and hippocampus. Symptoms were measured with neuropsychological and psychological tests, prioritizing outcomes related to striatal function. RESULTS: The study population included 40 participants (mean [SD] age, 32.9 [12.3] years). The TSPO V(T) across the regions of interest was greater in persons with COVID-DC (mean [SD] age, 32.7 [11.4] years; 12 [60%] women) compared with healthy control participants (mean [SD] age, 33.3 [13.9] years; 11 [55%] women): mean (SD) difference, 1.51 (4.47); 95% CI, 0.04-2.98; 1.51 divided by 9.20 (17%). The difference was most prominent in the ventral striatum (mean [SD] difference, 1.97 [4.88]; 95% CI, 0.36-3.58; 1.97 divided by 8.87 [22%]) and dorsal putamen (mean difference, 1.70 [4.25]; 95% CI, 0.34-3.06; 1.70 divided by 8.37 [20%]). Motor speed on the finger-tapping test negatively correlated with dorsal putamen TSPO V(T) (r, −0.53; 95% CI, −0.79 to −0.09), and the 10 persons with the slowest speed among those with COVID-DC had higher dorsal putamen TSPO V(T) than healthy persons by 2.3 (2.30 divided by 8.37 [27%]; SD, 2.46; 95% CI, 0.92-3.68). CONCLUSIONS AND RELEVANCE: In this case-control study, TSPO V(T) was higher in patients with COVID-DC. Greater TSPO V(T) is evidence for an inflammatory change of elevated gliosis in the brain of an individual with COVID-DC. Gliosis may be consequent to inflammation, injury, or both, particularly in the ventral striatum and dorsal putamen, which may explain some persistent depressive and cognitive symptoms, including slowed motor speed, low motivation or energy, and anhedonia, after initially mild to moderate COVID-19 illness.